Sudeep Pharma Limited Share Price & Stock Analysis

Sudeep Pharma Limited (NSE: SUDEEPPHRM, BSE: 544619) is a Vadodara, Gujarat-based company in the Excipients and Mineral Actives industry. With a market capitalisation of ₹13,641 Cr, it ranks #495 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹1,195.60 (as of 16 Nov 2026), the share price is 13.2% below its 52-week high of ₹1,378.00 and 128.1% above its 52-week low of ₹524.05.

Key Metrics

Current Price₹1,195.60
Market Cap₹13,641 Cr
NSE SymbolSUDEEPPHRM
BSE Code544619
SectorMaterials > Chemicals > Speciality Chemicals
Sub-IndustrySpecialty Chemicals > Excipients and Mineral Actives
P/E Ratio77.9
Return on Equity19.41%
Return on Assets13.68%
52-Week Range₹524.05 – ₹1,378.00
3-Month Price Change+8.9%
Beta (1Y)0.35
Dividend Yield0.12%
HeadquartersVadodara, Gujarat
Websitewww.sudeeppharma.com

Latest Quarterly Results — Q2 FY27

Revenue₹197 Cr
Net Profit₹52 Cr
Net Margin26.3%
EPS (Basic)₹4.59
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Sudeep Pharma Limited Quarterly Revenue and Profit Trend

Sudeep Pharma Limited reported revenue of ₹197 Cr in Q2 FY27, up 20.9% from ₹163 Cr in Q2 FY26 and up 24.3% from ₹158 Cr in Q1 FY27. It posted a net profit of ₹52 Cr for the quarter, against a net profit of ₹47 Cr in Q2 FY26 (up 10.8%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹158 Cr (Q1 FY27) to ₹197 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹197 Cr₹52 Cr26.3%
Q1 FY27₹158 Cr₹41 Cr25.6%
Q4 FY26₹182 Cr₹49 Cr26.6%
Q3 FY26₹172 Cr₹48 Cr27.7%
Q2 FY26₹163 Cr₹47 Cr28.8%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 76.15% of Sudeep Pharma Limited's shares as of Sept 2026, unchanged from Nov 2025. Delivery averaged 45.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Sudeep Pharma Limited

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceu

Products and Services

1. Pharmaceutical, Food and Nutrition-This segment offers pharmaceutical, food, and nutrition products. 2. Specialty Ingredients-This segment offers speciality ingredient. 3. Unallocated-NA 4. Specialty Chemicals-This segment offers specialty chemicals.

Business Segments

1. Pharmaceutical, Food and Nutrition-56.5% 2. Specialty Ingredients-43.5%

Frequently Asked Questions

What is the current share price of Sudeep Pharma Limited?

Sudeep Pharma Limited is trading at ₹1,195.60, with a market capitalisation of ₹13,641 Cr.

Which sector does Sudeep Pharma Limited belong to?

Sudeep Pharma Limited operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Excipients and Mineral Actives).

What are the key financial ratios of Sudeep Pharma Limited?

Sudeep Pharma Limited has a P/E of 77.9 and a return on equity of 19.41%.

What is the stock symbol of Sudeep Pharma Limited?

Sudeep Pharma Limited is listed on the NSE under the symbol SUDEEPPHRM and on the BSE under the scrip code 544619.

What were Sudeep Pharma Limited's latest quarterly results?

In Q2 FY27, Sudeep Pharma Limited reported revenue of ₹197 Cr and net profit of ₹52 Cr, with basic EPS of ₹4.59 (consolidated, parsed from the company's exchange filing).

How have Sudeep Pharma Limited's revenue and profit changed over the past year?

Sudeep Pharma Limited reported revenue of ₹197 Cr in Q2 FY27, up 20.9% from ₹163 Cr in Q2 FY26 and up 24.3% from ₹158 Cr in Q1 FY27.

What is the promoter holding in Sudeep Pharma Limited?

Promoters held 76.15% of Sudeep Pharma Limited's shares as of Sept 2026, unchanged from Nov 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.